Last reviewed · How we verify

American Health Research — Portfolio Competitive Intelligence Brief

American Health Research pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Guafenesin tablets Guafenesin tablets marketed Expectorant Respiratory

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. EMS · 1 shared drug class
  2. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 shared drug class
  3. Liaoning University of Traditional Chinese Medicine · 1 shared drug class
  4. Reckitt Benckiser Inc. · 1 shared drug class
  5. Reckitt Benckiser LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for American Health Research:

Cite this brief

Drug Landscape (2026). American Health Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/american-health-research. Accessed 2026-05-17.

Related